Bridge Biotherapeutics Signs Research Collaboration Agreement with US Scripps Research
[Asia Economy Reporter Chunhee Lee] Innovative drug research and development company Bridge Biotherapeutics announced on the 8th that it has signed a research collaboration agreement with The Scripps Research Institute, a top-tier global biomedical research institute in the United States.
Bridge Biotherapeutics plans to explore technologies that will serve as the foundation for discovering innovative new drugs through collaboration with Dr. Phil Barron and Dr. Benjamin Cravatt’s team, leaders in synthetic drug research based on Covalent Targeting technology. Utilizing this, the company aims to build an exclusive innovative drug discovery platform while gradually expanding areas such as protein degradation technology in drug development.
Under this research collaboration agreement, The Scripps Research Institute will be responsible for research and development activities related to the project for two years. Bridge Biotherapeutics will hold an option to exclusively license and patent rights worldwide for the follow-up development and commercialization of the technology from the project.
Dr. Barron said, "We are honored to proceed with this collaboration based on our expertise in drug research utilizing chemoproteomics,” adding, “Covalent targeting research on non-cysteine residues is an unknown and less explored area, and we hope this study will lead to the discovery and development of innovative drug candidates in the fields of immunology and oncology.”
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Christopher Kim, Vice President in charge of Bridge Biotherapeutics’ U.S. operations, stated, “The research collaboration with The Scripps Research Institute will open new paths for our innovative drug discovery and development direction, focusing on tumorigenic mutations and others,” and added, “We will strive to discover numerous highly selective drugs based on the platform to address unmet medical needs across various disease areas.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
